搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按时间排序
按相关度排序
centerforbiosimilars
14 小时
Biosimilar Rituximab Safe, Effective for SLE After Switching
A study found that switching from rituximab to biosimilar CT-P10 is safe and effective for patients with systemic lupus ...
centerforbiosimilars
1 天
BioRationality—The Evolution of the BPCIA and the Bright Future of Biosimilars in the US
The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar ...
centerforbiosimilars
2 天
Biosimilars Policy Roundup for September 2024—Podcast Edition
On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which ...
centerforbiosimilars
3 天
Treatment Persistence, Safety After Switching to Infliximab Biosimilars in Canadians With IBD
A retrospective study of a mandatory nonmedical switch in Canada found no significant differences in rates of treatment persistence, loss of response, or adverse events in patients with inflammatory ...
centerforbiosimilars
4 天
Eye on Pharma: High-Strength Trastuzumab Biosimilar; Originator Coverage Removals; CHMP ...
The FDA approved a new strength of a trastuzumab biosimilar; UnitedHealth will remove reference adalimumab from some ...
centerforbiosimilars
4 天
The Top 5 Biosimilar Articles for the Week of September 30
Number 3: Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while ...
centerforbiosimilars
7 天
Biosimilar Policy Roundup—September 2024
In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈